Drug intelligence / Profile preview

autologous bone marrow stem cells

Development stage: Phase 3
Lead developer: Global Cell Med
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

Autologous bone marrow stem cells are a cell therapy being investigated by Global Cell Med for the treatment of chronic insulin-dependent type 1 and type 2 diabetes mellitus. The therapy involves harvesting a patient's own bone marrow stem cells and re-administering them without prior cell culture or immunosuppression. The mechanism of action is thought to involve immune modulation, the promotion of angiogenesis, and the stimulation of quiescent endogenous stem cells to regenerate pancreatic function and enhance endogenous insulin secretion, thereby improving glycemic control.

Other names: Adult Bone Marrow Stem CellsAutologous Bone Marrow Stem Cell Transplantation

Beyond the preview

Go deeper on autologous bone marrow stem cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous bone marrow stem cells.

Explore the full profile